行情

KURA

KURA

Kura Oncology
NASDAQ

实时行情|Nasdaq Last Sale

9.70
+0.71
+7.90%
盘后 16:00 04/09 EDT
开盘
9.20
昨收
8.99
最高
9.75
最低
9.14
成交量
27.27万
成交额
--
52周最高
21.42
52周最低
6.35
市值
4.41亿
市盈率(TTM)
-6.4443
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测KURA价格均价为27.14,最高价位30.00,最低价为22.00。

EPS

KURA 新闻

更多
  • 白俄罗斯总理建议欧亚经济联盟大力推动去美元化进程
  • 央视 · 1小时前
  • 摩根大通大幅下调对美国经济前景的预期
  • 新浪财经综合 · 1小时前
  • 2.3万亿美元并非最后一搏,美联储还能继续放水!
  • 新浪财经综合 · 1小时前
  • 美股战“疫”小记:美股在这个早春都经历了什么?
  • 新浪财经综合 · 1小时前

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

KURA 简况

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
展开

微牛提供Kura Oncology Inc(NASDAQ-KURA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的KURA股票新闻,以帮助您做出投资决策。